Industry Briefs

Forget filling out grant applications or begging your department head for discretionary funds - your next research award may come courtesy of the daily papers. Last month, two of Canada's leading newspapers, The Globe and Mail and La Presse, ran full-page ads that shouted in end-of-the-world-size type: "ATTENTION SCIENTISTS. $1 MILLION GRANT AVAILABLE FOR DISCOVERY OF NON-INVASIVE MEANS TO DETECT GASTROINTESTINAL DAMAGE CAUSED BY ARTHRITIS MEDICATIONS." Placed by Searle Canada Inc., the ad was

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Forget filling out grant applications or begging your department head for discretionary funds - your next research award may come courtesy of the daily papers. Last month, two of Canada's leading newspapers, The Globe and Mail and La Presse, ran full-page ads that shouted in end-of-the-world-size type: "ATTENTION SCIENTISTS. $1 MILLION GRANT AVAILABLE FOR DISCOVERY OF NON-INVASIVE MEANS TO DETECT GASTROINTESTINAL DAMAGE CAUSED BY ARTHRITIS MEDICATIONS." Placed by Searle Canada Inc., the ad was intended to reach as broad an audience as possible: scientists and engineers as well as physicians. "Instead of putting an ad in a lot of different journals, we decided to put it in the paper," said Anne Brusby, medical director for Searle. An independent committee of university-affiliated gastroenterologists, rheuma- tologists, and research consultants will decide, based upon formal applications filled out by respondents to the ad, the winner of the $1 million award. Think you've developed ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies